Studies on the concentrations of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) in dog plasma and cerebral spinal fluid

Japanese Pharmacology and Therapeutics

Volumn 25, Issue SUPPL. 7, 1997, Pages 286-287

  Takamatsu, Yasuo ^a   Watanabe, Toshiaki ^a  

^a MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

Blood brain barrier; Cerebral spinal fluid; MCI 186; Plasma

Indexed keywords

NORPHENAZONE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; GAS CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; NONHUMAN;

EID: 0031461255     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Kontos HA : Oxygen radicals in cerebral vascular injury. Circ Res 57: 508-516, 1985
2. Halliwell B : Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623, 1992
3. Watanabe T et al : Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukotrienes Essent Fatty Acids 33: 81-87, 1988
4. Watanabe T et al : Protective effects of MCI-186 on cerebral ischemia ; Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 268: 1597-1604, 1994
5. Abe K et al : Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 19: 480-485, 1988
6. Nakagomi T et al : Effect of a new free radical scavenger, MCI-186, on experimental cerebral vasospasm. Sano K et al ed, Cerebral Vasospasm. p141-142, University of Tokyo Press, 1990
7. 3-Methyl-1-phenyl-2-pyrazolin-5-one(MCI-186) 11(5): 451-462, 1996
8. 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) 25(Suppl 7): s1785- 1791, 1997